Athersys is a development stage biotech that fully enrolled a Phase 2 stem cell trial for ischemic stroke at the end of 2014. Results will likely be a binary event: company crippling or validating MultiStem for ischemic stroke and many other significant indications.
http://ift.tt/1IrYNqa
http://ift.tt/1IrYNqa
No comments:
Post a Comment